文献速递甲状腺疾病

灭活与mRNA新冠疫苗接种对接受甲状腺功能亢进治疗患者甲状腺功能的影响

Effect of Inactivated and mRNA COVID-19 Vaccination on Thyroid Function Among Patients Treated for Hyperthyroidism.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

该研究纳入2021年1月至9月在一家教学医院甲状腺门诊就诊的910例接受甲状腺功能亢进治疗的患者,比较接种与未接种新冠疫苗者的甲状腺功能不稳定风险。中位随访5.3个月,疫苗接种未增加甲状腺功能不稳定风险(HR 0.78,95%CI 0.56-1.09,P=0.151),甲状腺功能异常与未接种状态独立相关。

要点

  • 在甲状腺功能亢进治疗患者中,疫苗接种未增加甲状腺功能不稳定风险(HR 0.78,95%CI 0.56-1.09,P=0.151)。
  • 甲状腺功能异常和心血管合并症与未接种疫苗状态独立相关。
  • 接种时明显甲状腺毒症的27例患者接种疫苗后未触发甲状腺风暴或后续甲状腺功能控制困难。

核心结论

  • 在接受甲状腺功能亢进治疗的患者中,甲状腺功能异常是预测未接种疫苗状态的因素;研究结果应鼓励这些患者接种新冠疫苗以保护自身免受新冠不良结局和潜在长期后遗症的影响。

研究设计与样本

  • 研究纳入2021年1月至9月在一家教学医院甲状腺门诊连续就诊的接受甲状腺功能亢进治疗的患者,分为接种组和未接种组,接种组以第一剂疫苗接种日期为索引日期,未接种组以纳入期间首次就诊日期为索引日期,随访至2022年3月或发生甲状腺功能不稳定(甲状腺功能恶化/抗甲状腺药物剂量增加),以先发生者为准。

主要发现

  • 共纳入910例患者(平均年龄51.6岁;82.1%为女性),其中86.2%为Graves病,67.3%已接种疫苗(67.3%接种BNT162b2;30.6%接种CoronaVac;2.1%接种异源疫苗)。
  • 中位随访5.3个月,15.9%的患者发生甲状腺功能不稳定。
  • 新冠疫苗接种未增加甲状腺功能不稳定风险(风险比0.78,95%CI 0.56-1.09,P=0.151);在Graves病、两种疫苗类型以及无论基线甲状腺功能是否正常的情况下,结果一致。
  • 27例接种时明显甲状腺毒症的患者接种新冠疫苗后未触发甲状腺风暴或后续甲状腺功能控制困难。
  • 甲状腺功能异常和心血管合并症与未接种疫苗状态独立相关。

临床怎么用

  • 作者认为,研究结果应鼓励接受甲状腺功能亢进治疗的患者接种新冠疫苗,以保护自身免受新冠不良结局和潜在长期后遗症的影响。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Reports of thyroid dysfunction following COVID-19 vaccination included cases of relapse of Graves' disease and worsening of pre-existing Graves' disease. Little is known about the thyroid-specific outcomes among patients treated for hyperthyroidism who have received COVID-19 vaccination. OBJECTIVE: Among patients treated for hyperthyroidism, we evaluated factors associated with not receiving the COVID-19 vaccination and whether COVID-19 vaccination was associated with thyroid function instability. METHODS: We included consecutive patients treated for hyperthyroidism attending the thyroid clinic at a teaching hospital between January and September 2021. They were categorized into vaccinated and unvaccinated groups. The index date was the date of first-dose vaccination for the vaccinated group, and the first date of attendance in the inclusion period for the unvaccinated group. They were followed up until March 2022 or occurrence of thyroid function instability (worsening of thyroid function/increase in antithyroid drug dosage), whichever was earlier. RESULTS: A total of 910 patients were included (mean age 51.6 years; 82.1% female). Of these, 86.2% had Graves disease and 67.3% were vaccinated (67.3% BNT162b2; 30.6% CoronaVac; 2.1% heterologous). Abnormal thyroid function and cardiovascular comorbidities were independently associated with unvaccinated status. Upon median follow-up of 5.3 months, thyroid function instability occurred in 15.9% of patients. COVID-19 vaccination did not increase risks of thyroid function instability (hazard ratio 0.78, 95% CI 0.56-1.09, P = .151); this was consistent in Graves disease, both types of vaccines, and regardless of whether baseline thyroid function was normal. Twenty-seven patients overtly thyrotoxic at the time of vaccination received COVID-19 vaccines without triggering a thyroid storm or difficulty in subsequent thyroid function control. CONCLUSION: Among patients treated for hyperthyroidism, abnormal thyroid function was a factor predicting unvaccinated status. Our results should encourage patients treated for hyperthyroidism to receive COVID-19 vaccination to protect themselves from adverse outcomes and potential long-term sequelae of COVID-19.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Wong CH, Leung EKH, Tang LCK, et al. Effect of Inactivated and mRNA COVID-19 Vaccination on Thyroid Function Among Patients Treated for Hyperthyroidism. J Clin Endocrinol Metab. 2023. PMID: 36453154. doi:10.1210/clinem/dgac684

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。